KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of GoodwillAmortization of GoodwillAmortizatization of IntangiblesAmortizatization of IntangiblesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Exchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeOther financing activitiesOther financing activitiesSales of Property, Plant and EquipmentSales of Property, Plant and EquipmentShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ginkgo Bioworks Holdings (DNA) Change in Accured Expenses (2020 - 2025)

Ginkgo Bioworks Holdings filings provide 6 years of Change in Accured Expenses readings, the most recent being -$6.6 million for Q4 2025.

  • On a quarterly basis, Change in Accured Expenses rose 29.17% to -$6.6 million in Q4 2025 year-over-year; TTM through Dec 2025 was $10.4 million, a 125.66% increase, with the full-year FY2025 number at $10.4 million, up 125.66% from a year prior.
  • Change in Accured Expenses hit -$6.6 million in Q4 2025 for Ginkgo Bioworks Holdings, down from $22.1 million in the prior quarter.
  • In the past five years, Change in Accured Expenses ranged from a high of $22.1 million in Q3 2025 to a low of -$42.0 million in Q3 2024.
  • Median Change in Accured Expenses over the past 5 years was $1.7 million (2021), compared with a mean of -$400300.0.
  • Biggest five-year swings in Change in Accured Expenses: surged 178.17% in 2023 and later plummeted 164814.29% in 2025.
  • Ginkgo Bioworks Holdings' Change in Accured Expenses stood at $15.2 million in 2021, then crashed by 282.85% to -$27.8 million in 2022, then soared by 178.17% to $21.7 million in 2023, then plummeted by 143.0% to -$9.3 million in 2024, then increased by 29.17% to -$6.6 million in 2025.
  • The last three reported values for Change in Accured Expenses were -$6.6 million (Q4 2025), $22.1 million (Q3 2025), and -$11.5 million (Q2 2025) per Business Quant data.